TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total hours from surgery end to out of the operating room
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Coma Recovery Scale - Revised score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Semen quality analysis - motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Semen quantity analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Semen quality analysis - shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sensitivity and specificity of screening tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotypical and functional changes of T cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence Rate of the Composite Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence Rate of Valve Malpositioning
Endpoint domain: Adverse events/effects
Primary endpoint: INSPIRIS RESILIA Valve Expansion Post Valve in Valve Procedure Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite of MAE
Endpoint domain: Adverse events/effects
Primary endpoint: Investigational Device Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average Richmond Agitation Sedation Scale (RASS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experience treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cross-reactive Antigenemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete success by efficacy and safety criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-intervention alcohol beverage consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bleeding on Probing %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Neurofilament Light (NfL) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Blood Glial Fibrillary Acidic Protein (GFAP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Blood Amyloid Beta 42/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in P-tau 181
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Blood Interleukin-6 (IL-6) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of misoprostol acid in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Soft and Hard Tissue Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving 4-Component Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of prostate embolization
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarker dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with laboratory abnormalities defined as dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of prediction of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uterine blood supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tinnitus loudness (CI electrical stimulation intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective electroencephalography-based assessment (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on Dementia Cognitive Fluctuations Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peak Intensity (PI) at CEUS imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak (TTP) at CEUS imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between fibrinogen measurement methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to first given rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful insert rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The scale of fiberoptic bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with cranial nerve injury
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment completion (relative dose)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global health status (GHS) scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score from the FACIT Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Comparison of treatment efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive value of ctDNA to monitor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attitudes and Beliefs about Complementary and Alternative Medicine Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Cancer Behavior Inventory (Brief Form)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in pain-intensity scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in pain-interference scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Validation of food frequency questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphological of tubal cilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular difference in tubal cilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional composition of tubal cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 dose of DFP-10917
Endpoint domain: Adverse events/effects
Primary endpoint: Emotion recognition
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Emotion understanding
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Emotional-mental vocabulary
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time to hospitalization for worsening HF or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Tolerated Dose (MTD) of ribociclib and belinostat combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sternal wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maxillary incisors inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with a need for QoL therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Minimum Observed Concentration (Cmin) at Week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Observed Concentration (Cmin) at Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Observed Concentration (Cmax) at Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration Over the Dosing Interval (Cavg) at Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term efficacy of the twinkling marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Esophageal pressure-time product (PTPoes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diaphragmatic pressure-time product (PTPdi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dynamic brain state change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Technical success of EUS-GBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical success of EUS-GBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to receive first postoperative analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes with complete reabsorption of intraretinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular Edema - Central Subgroup Thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision, best corrected, logMAR units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of percutaneous liver biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Wechsler Memory Scale (WMS-IV) Older Adult Battery Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective experiential outcome after ICU admission
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients able to use the serious game without side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Adverse Event Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Time between skin puncture and removal of the needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in lipidomic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in polar metabolite profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients successfully ceasing ADs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAR positive T cells in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intrahepatic Triglyceride (IHTG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in World Health Organization Ordinal Scale for clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of information regarding polygenic risk score and early detection assays
Endpoint domain: Life impact
Endpoint subdomain: Decision making
Primary endpoint: Incidence of grade 3-5 adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Neural excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transcutaneous carbon dioxide pressure (TcPCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety State Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PBMC characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum inflammatory cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean time spent on intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients who improve in ability to do things that are important before and after intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients who report a reduction in medication burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in intention to adhere to adjuvant endocrine therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in adjuvant endocrine therapy knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in attitude towards adjuvant endocrine therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wrinkle reduction efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of high grade dysplasia and esophageal adenocarcinoma lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Short Form - 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Umbilical Cord Arterial pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVPA ratio before and after biological therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in simulated emergency trauma care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Motor-evoked potential (MEP) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fugl-Meyer upper extremity assessment of sensorimotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-related desynchronization (ERD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Achievement of a complete response (CR)
Endpoint domain: Mortality/survival
Primary endpoint: Serum concentration of glofitamab in combination with R-ICE chemoimmunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration (Cmax) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of maximum plasma concentration (tmax) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve (AUC) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real-World Disease Free Survival (rwDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with high pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta of peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal wall tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illness-related distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Usability of the Omnidirectional Treadmill and Virtual Reality Game
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Harris functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Semi-quantitative tenderness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SOLAR score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: First time up and about
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recovery time of intestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean number of days of negative pressure delivered to the incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pain score VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary endocan level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage to PrEP services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total enrollment at 1.5 years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention rate at study conclusion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in rate of perceived exertion (RPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant psoriasis Body Surface Area (BSA) involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global cognitive score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with non-serious adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant changes in physical examination, laboratory parameters, vital signs, and 12 lead electrocardiogram (ECG) findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant changes in Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events associated with the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Corrected QT Interval by Fridericia (QTcF Interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thalamic seizure detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: levels of maternal and fetal serum soluble Fms-like tyrosine kinase-1 (sFlt-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: levels of seromucoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of protein-bound hexose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with adverse events (AEs)/treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with potentially clinically significant abnormalities (PCSAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of engagement in treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Postoperative Knee Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature, frequency, and severity of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Validation of GPAT scoring tool for polypectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute rejection of liver transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in bone-to-bone contact between tuberosity and acromion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: single assessment numerical evaluation (SANE) of the shoulder
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: American shoulder and elbow surgeons (ASES) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diabetes Self-Care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doctor Visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: MADRS scale changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved area under receiver operating curve (ROC) to predict CAD-RADS ≥3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Motor Coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Manual Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes